Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to better understand the outcomes of active surveillance (observation) instead of immediate surgery, which is the current standard of care for papillary thyroid microcarcinoma (PTMC). Patients with a 1.5 cm or smaller thyroid nodule(s) with papillary thyroid carcinoma will be eligible for the study.
The incidence of thyroid cancer has more than doubled in the last 30 years in the United States, Europe, Canada, and South America. Since nearly 50% of this increase is attributable to papillary thyroid microcarcinomas (PTMC), it appears that greater detection and diagnosis of previously subclinical disease is a major factor driving this dramatic rise.
The primary objective is to estimate the rate of disease progression (growth of primary tumor or development of loco-regional/distant metastases) over a 3, 5, and 10-year period in a series of PTMC patients followed with active surveillance in the United States.
Patients who opt for immediate surgery can participate in a sub-study looking at quality of life and anxiety measures as compared to those patients who enroll in the active surveillance main study. Patients who enroll in active surveillance can choose to have surgery at any time that they and their treating physician feel that it is in their best interest.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Active Surveillance | Other | Active surveillance instead of standard of care immediate surgery. Patients will be closely monitored every six months until disease is stable for a two-year period and then annually thereafter. |
|
| Immediate Surgery | No Intervention | Patients who choose to get surgery immediately after diagnosis may choose to enroll in a questionnaire sub-study that will compare quality of life and anxiety scores to patients who enroll in the active surveillance study. This is considered "no intervention" because the protocol is not directing treatment. Surgery is the standard treatment for papillary thyroid microcarcinoma. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Active Surveillance | Other | Subjects will be actively observed for disease progression (condition worsens) instead of receiving immediate surgery, considered standard of care. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Rate of disease progression | From time of diagnosis up to10 years of follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of subjects that will elect surgery despite absence of clinical progression | From time of diagnosis up to 10 years of follow-up | |
| Impact of TSH suppression on thyroid nodule growth (in cm) as measured by ultrasound | Five years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Allen Ho, MD | Contact | 310-423-1220 | Allen.Ho@cshs.org | |
| Clinical Trials Navigator | Contact | GroupCancerTrialInformation@cshs.org |
| Name | Affiliation | Role |
|---|---|---|
| Allen Ho, MD | Cedars-Sinal Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cedars-Sinai Medical Center | Recruiting | Los Angeles | California | 90048 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36107411 | Derived | Ho AS, Kim S, Zalt C, Melany ML, Chen IE, Vasquez J, Mallen-St Clair J, Chen MM, Vasquez M, Fan X, van Deen WK, Haile RW, Daskivich TJ, Zumsteg ZS, Braunstein GD, Sacks WL. Expanded Parameters in Active Surveillance for Low-risk Papillary Thyroid Carcinoma: A Nonrandomized Controlled Trial. JAMA Oncol. 2022 Sep 15;8(11):1588-96. doi: 10.1001/jamaoncol.2022.3875. Online ahead of print. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C563277 | Papillary Thyroid Microcarcinoma |
| D013964 | Thyroid Neoplasms |
| ID | Term |
|---|---|
| D004701 | Endocrine Gland Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D006258 | Head and Neck Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D057832 | Watchful Waiting |
| ID | Term |
|---|---|
| D017063 | Outcome Assessment, Health Care |
| D010043 | Outcome and Process Assessment, Health Care |
| D011787 | Quality of Health Care |
| D006298 | Health Services Administration |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Identify the clinicopathologic features associated with disease progression in papillary thyroid microcarcinoma patients followed with active surveillance | Five years |
| Identify the genetic factors associated with an increased risk of disease progression | At any time subjects who have enrolled in the active surveillance study can opt to have surgery. Data will be taken from diagnosis to just after surgery. | Five years |
| Quality of life score as measured by City of Hope Quality of Life Scale | Up to five years |
| Anxiety score as measured by Memorial Anxiety Scale | Up to five years |
| D004700 |
| Endocrine System Diseases |
| D013959 | Thyroid Diseases |